other material
confidence high
sentiment positive
materiality 0.75
Korro Bio closes $70M private placement to fund Phase 1/2 trial of KRRO-110
Korro Bio, Inc.
- Sold 1,249,283 shares at $56.00 per share for gross proceeds of ~$70M.
- Led by Deep Track Capital; includes Atlas Venture, Blue Owl, NEA, Rock Springs, Tri Locum.
- Proceeds plus existing $166.4M cash to fund Phase 1/2 trial of KRRO-110 in AATD through 2026.
- Piper Sandler, RBC Capital, BMO Capital Markets acted as placement agents.